Microdosing mushrooms means taking a very small amount of psilocybin mushrooms, typically one-tenth to one-twentieth of a recreational dose, on a regular schedule. The goal isn’t to trip or hallucinate. Instead, people take these sub-perceptual doses hoping to subtly improve mood, creativity, or focus over time. The practice has grown from a niche biohacking trend into a widely discussed wellness topic, but the science behind it is still catching up to the enthusiasm.
How a Microdose Differs From a Full Dose
A full recreational dose of dried psilocybin mushrooms typically ranges from 2 to 5 grams and produces vivid visual distortions, altered sense of time, and intense emotional experiences lasting 4 to 6 hours. A microdose sits far below that threshold, generally between 0.1 and 0.3 grams of dried mushrooms. At this level, you shouldn’t feel “high” in any obvious way. The idea is that the dose is sub-perceptual: low enough that you could go about a normal workday without anyone noticing, but high enough that something is happening in the brain.
People who microdose don’t take a dose every day. The most popular approach, known as the Fadiman protocol, involves one dosing day followed by two days off before the next dose. This cycle repeats for several weeks, then users typically take a longer break. The rest days are considered important both to avoid building tolerance and to let users compare how they feel on dosing versus non-dosing days.
Another common approach, associated with mycologist Paul Stamets, pairs the psilocybin microdose with lion’s mane mushroom and niacin (vitamin B3). Survey data from a large study of microdosers found that 39% added lion’s mane to their regimen, 18% added niacin, and 16% combined both. Standardized dosages for these additions haven’t been established in clinical research.
What Psilocybin Does in the Brain
Once ingested, psilocybin is converted in the body to psilocin, its active form. Psilocin binds to serotonin receptors, particularly a type called 5-HT2A, which are concentrated in the brain’s cortex. This is the same receptor targeted by full psychedelic doses, just stimulated far less intensely at microdose levels.
The more interesting theory behind microdosing involves neuroplasticity, the brain’s ability to form and reorganize connections between neurons. Animal research shows that psilocybin and similar compounds can promote the growth of new synapses and increase levels of proteins involved in maintaining healthy neural connections. A study in pigs found that a single dose of psilocybin increased a key marker of synaptic density in the brain. These structural changes appear to work through a chain of signaling pathways triggered by that initial serotonin receptor activation, ultimately stimulating growth and repair processes in brain cells.
This is the biological rationale that microdosing advocates point to: even a tiny dose might gently nudge the brain toward forming new connections, potentially explaining the improvements in mood and cognitive flexibility that users report. Whether microdoses are actually large enough to trigger meaningful neuroplasticity in humans remains an open question.
What People Report Feeling
Surveys of microdosers consistently show that they report reduced anxiety and depression, improved focus, and greater emotional openness. A large observational study found that adults who microdosed psychedelics reported lower levels of anxiety and depression compared to non-microdosers, and many cited mental health as their primary motivation for the practice.
Creativity is another commonly cited benefit. Users describe finding it easier to make unexpected connections between ideas or approach problems from new angles. These reports are compelling in their consistency, but they come with a significant caveat.
The Placebo Problem
The biggest challenge facing microdosing research is separating genuine drug effects from expectation. When people believe they’re taking something that will make them more creative or less anxious, that belief alone can produce real, measurable changes in how they feel and perform.
Double-blind, placebo-controlled studies of microdosing, where neither the participant nor the researcher knows who got the real dose, have produced far less impressive results than the glowing self-reports suggest. In these controlled settings, the improvements reported by people taking psilocybin often aren’t significantly different from those reported by people taking a placebo. This doesn’t necessarily mean microdosing does nothing, but it does mean that expectation and ritual may account for a large portion of the benefits people experience. The act of committing to a protocol, paying attention to your mental state, and believing you’re doing something positive for your brain could itself be therapeutic.
Cardiovascular Risks Worth Knowing About
One safety concern that gets little attention in popular discussions of microdosing involves the heart. Psilocin doesn’t just bind to serotonin receptors in the brain. It also activates a related receptor type called 5-HT2B, found on cells in the heart valves. When drugs stimulate these receptors repeatedly over months, the valve tissue can thicken and stiffen, a condition called valvular heart disease.
This isn’t a theoretical concern. Other drugs that strongly activate this same receptor have been pulled from the market for causing heart valve damage. Psilocin’s binding strength at this receptor is comparable to several of those withdrawn drugs. Research has shown that even a small 3 mg dose of psilocybin raises blood levels of psilocin to concentrations comparable to those seen with known valve-damaging compounds. Duration of use plays a major role in this type of heart damage. Converging evidence suggests that stimulation of these receptors over several months can lead to fibrosis, even when the substance isn’t taken daily.
No long-term cardiac studies have been completed specifically on people who microdose psilocybin, so the actual real-world risk remains unknown. But the pharmacological profile gives researchers reason for caution, particularly for people who microdose on extended schedules lasting many months.
Common Side Effects
Beyond the cardiovascular question, the more immediate side effects of microdosing tend to be mild. Users commonly report slight nausea (psilocybin mushrooms are hard on the stomach even at low doses), difficulty sleeping if the dose is taken too late in the day, and occasional headaches. Some people find that microdoses make them feel slightly jittery or overstimulated, particularly at the higher end of the dosing range. Finding the right amount often involves some trial and error, and what’s sub-perceptual for one person may be noticeably psychoactive for another, since mushroom potency varies widely even within the same batch.
Legal Status in the United States
Psilocybin remains a Schedule I controlled substance under federal law, making it illegal to possess, sell, or manufacture nationwide. However, the legal landscape at the state and local level has shifted significantly in recent years.
Oregon became the first state to create a regulated psilocybin services program in 2020, allowing supervised use at licensed facilities. Colorado followed in 2022 with Proposition 122, establishing its own regulated access framework. New Mexico signed the Medical Psilocybin Act in April 2025, making it the third state to create a regulated system, with services expected to launch in late 2026.
Several other states have carved out narrower paths. Utah, Washington, Connecticut, and New Jersey have created pilot programs offering psilocybin therapy to specific groups like veterans and first responders. Indiana and Texas have funded research programs. At the city level, Oakland, Santa Cruz, San Francisco, Berkeley, and several other California cities have passed resolutions making enforcement of laws against psilocybin possession the lowest police priority.
None of these programs are designed with self-directed microdosing in mind. The regulated access models in Oregon and Colorado involve supervised sessions at licensed centers, not take-home supplies. For someone microdosing on their own, the practice remains illegal in most of the country regardless of these state-level changes.